PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

AstronauTx completes £48m series A financing for Alzheimer’s disease

The financing will support the biotech’s clinical study of people with AD as a lead programme.

AstronauTx has announced the completion of a £48m Series A financing to create new treatments for Alzheimer’s disease (AD).

As part of the investment led by the Novartis Venture Fund, the financing was supported by several global venture investors, including Brandon Capital, Bristol Myers Squibb, EQT Life Sciences from the LSP Dementia Fund and MPM Capital with support from the Dementia Discovery Fund.

All proceeds from the Series A financing will be used to develop the London-based biotech company, AstronauTx, and advance its portfolio of small-molecule drugs, including a clinical study of AD patients as a lead programme.

Dr Marianne Uteng, managing director at the Novartis Venture Fund, said: “The founders and investors include world experts in neuroscience, and the founder’s discovery is thought to have potential in halting disease progression and improving patients’ quality of life.”

Jonathan Tobin, partner at Brandon Capital, said: “We are pleased to join the impressive syndicate of investors backing AstronauTx in its mission to create therapies that are expected to provide not only symptomatic but also disease-modifying benefits in Alzheimer’s and other neurological diseases, and area of high unmet need but where recent breakthroughs are offering new hope.”

The company will work on oral drugs that could be “applicable across multiple neurodegenerative conditions,” said its co-founder, Dr Ruth McKernan.

First launched in 2019, AstonauTx was created by the Dementia Discovery Fund with an additional £6.5m in seed funding provided from the UCL Technology Fund and the UK Future Fund to develop novel drugs to correct the disrupted physiology of the brain by improving the support function of astrocytes, an important cell type in the brain.

In July 2023, AstronauTx announced its partnership with Danish biotechnology company Saniona to identify new treatments by modulating a novel, undisclosed ion channel target.

Most recently, AstronauTx was awarded an Innovate UK grant in September to fund preclinical work on one of its programmes.

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026